Monomeric Targeted Protein Degraders
- 22 October 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (20), 11330-11361
- https://doi.org/10.1021/acs.jmedchem.0c00093
Abstract
The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacology. While engineered heterodimeric molecules have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degradation observed for smaller, monomeric molecules. Methods and tools for evaluating protein degradation as well as a discussion of physical properties of monomeric vs engineered heterodimeric degraders are presented.This publication has 195 references indexed in Scilit:
- Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone SubstrateACS Chemical Biology, 2012
- Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)Journal of Medicinal Chemistry, 2012
- A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer TreatmentJournal of Medicinal Chemistry, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycinNature Chemical Biology, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem CellsCell, 2009
- Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of ConjugationCell, 2008
- The Epigenomics of CancerCell, 2007
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006